Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Orv Hetil ; 157(8): 310-5, 2016 Feb 21.
Artigo em Húngaro | MEDLINE | ID: mdl-26876268

RESUMO

Graves' orbitopathy is the extrathyroidal manifestation of Graves' disease, which is the most common cause of exophthalmos. As eye symptoms usually coincide with the development of thyrotoxicosis, the diagnosis of the disease is rarely difficult. The aim of the authors was to summarize the differential diagnosis of Graves' orbitopathy based on literature review and presentation of their own four problematic cases on this topic. They conclude that symptoms similar to endocrine orbitopathy are present in other disorders. Endocrinologists need to be aware of these other conditions to avoid treatment failures.


Assuntos
Corticosteroides/uso terapêutico , Neoplasias Oculares/diagnóstico , Oftalmopatia de Graves/etiologia , Hipergamaglobulinemia/diagnóstico , Imunoglobulina G/sangue , Inflamação/diagnóstico , Leucemia Linfocítica Crônica de Células B/diagnóstico , Órbita/patologia , Tireotoxicose/diagnóstico , Corticosteroides/administração & dosagem , Adulto , Idoso , Diagnóstico Diferencial , Diplopia/etiologia , Neoplasias Oculares/complicações , Feminino , Oftalmopatia de Graves/tratamento farmacológico , Humanos , Hipergamaglobulinemia/complicações , Inflamação/complicações , Leucemia Linfocítica Crônica de Células B/complicações , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Doenças Orbitárias/diagnóstico , Tireotoxicose/complicações , Resultado do Tratamento
2.
Orv Hetil ; 155(33): 1295-300, 2014 Aug 17.
Artigo em Húngaro | MEDLINE | ID: mdl-25109914

RESUMO

Graves' orbitopathy is the most common extrathyroidal manifestation of Graves' disease. Up to now, curative treatment modalities for the most severe sight-threatening cases have not been developed. Here the authors summarize the treatment protocol of Graves' orbitopathy and review novel therapeutic options. They review the literature on this topic and present their own clinical experience. The authors point out that anti-CD20 antibody could positively influence the clinical course of Graves' orbitopathy. Selenium is efficient in mild cases. Further prospective investigations are warranted.


Assuntos
Anticorpos Monoclonais Murinos/uso terapêutico , Anticorpos Monoclonais/uso terapêutico , Antígenos CD20/imunologia , Oftalmopatia de Graves/terapia , Imunoglobulina G/uso terapêutico , Fatores Imunológicos/uso terapêutico , Receptores do Fator de Necrose Tumoral/uso terapêutico , Fator de Necrose Tumoral alfa/imunologia , Etanercepte , Oftalmopatia de Graves/imunologia , Humanos , Infliximab , Rituximab , Selênio/uso terapêutico
3.
Orv Hetil ; 164(41): 1616-1627, 2023 Oct 15.
Artigo em Húngaro | MEDLINE | ID: mdl-37987695

RESUMO

The growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis plays a crucial role in maintaining the normal function of the cardiovascular system. Results of the last decades demonstrated that GH-IGF-1 takes part in regulating peripheral resistance and contributes to preserving physiological cardiac mass and left ventricular function. Vasculoprotective functions of the GH-IGF-1 axis are believed to counteract atherosclerosis. Unlike in childhood, when GH-deficiency results in growth retardation, GH deficiency does not cause specific symptoms in adults. Adult growth hormone deficiency (AGHD) is characterized by a clustering of cardiometabolic risk factors resulting in a clinical picture similar to the metabolic syndrome. Besides visceral obesity, dyslipidemia and insulin resistance, novel cardiovascular risk factors, such as chronic low-grade inflammation, oxidative stress and prothrombotic state have also been reported in AGHD and may contribute to the increased cardiometabolic risk. Based on a growing body of evidence, long-term GH-replacement improves lipid profile significantly and has a favorable impact on body composition, endothelial function, left ventricular mass as well as the novel, non-traditional cardiometabolic risk factors. Increased mortality associated with the disease is now considered to be multicausal and as such cannot be solely attributed to the GH-deficiency. The etiology of GH-deficiency, treatment of the underlying pathology as well as the inadequate treatment of coexisting hormonal deficiencies might also be responsible for the increased mortality. Nevertheless, in hypopituitarism, adequate replacement therapy including GH-substitution may result in a mortality that is comparable to the general population. Orv Hetil. 2023; 164(41): 1616-1627.


Assuntos
Aterosclerose , Sistema Cardiovascular , Hipopituitarismo , Adulto , Humanos , Fator de Crescimento Insulin-Like I , Hipopituitarismo/complicações , Hipopituitarismo/tratamento farmacológico , Hormônio do Crescimento
4.
Orv Hetil ; 163(12): 463-472, 2022 03 20.
Artigo em Húngaro | MEDLINE | ID: mdl-35306479

RESUMO

Összefoglaló. Bevezetés: A pajzsmirigy-alulmuködés gyakori betegség. Kezelésében a levotiroxin (LT4)-pótlás a szokásos eljárás, mely tabletta vagy gélkapszula formájában áll rendelkezésre Magyarországon. A nemzetközi trendeknek megfeleloen az esetek korai felismerése miatt már a kevésbé kifejezett hormonális eltérések idején elindul a kezelés. Az endokrinológusok hypothyreosiskezelési szokásaival kapcsolatban Magyarországon és Európában felmérés eddig nem történt. Célkituzés: A THESIS (Treatment of Hypothyroidism in Europe by Specialists: an International Survey) célja, hogy felmérjük az európai és közte jelen munkánkban a magyar endokrinológusok hypothyreosiskezelési szokásait és az LT4 esetleges alkalmazását pajzsmirigy-muködészavarral nem járó állapotokban. Módszer: A Magyar Endokrinológiai és Anyagcsere Társaság (MEAT) tagjainak e-mailben meghívót küldtünk az online kérdoíves vizsgálathoz. Eredmények: 165 magyar endokrinológus válaszai alapján végeztük az elemzést. A válaszadók többsége, 99,4%-uk elso kezelésként LT4-pótlást alkalmaz. Az LT4 + LT3 kombinációt elsosorban olyan betegeknél alkalmazzák, akik LT4 szedése mellett euthyreoid hormonértékek ellenére hypothyreosisra jellemzo tüneteket mutatnak (36,1%). Euthyreoid hormonértékek mellett, magas antitestszint és infertilitás esetén 60,3% megfontolná LT4 indítását, amit evidenciák jelenleg nem indokolnak. Számos kórállapot befolyásolja az LT4 felszívódását, ezekben az esetekben a magyar endokrinológusok 66,4%-a preferálja a lágy kapszula alkalmazását, jobb eredményt várva a gyógyszerformák közötti váltástól. Következtetés: A pajzsmirigy-alulmuködés kezelésében a magyar endokrinológusok elsodlegesen az LT4-et választják. Az LT4 + LT3 kombinált alkalmazását a pajzsmirigy-stimuláló hormon normális szintjének elérése után perzisztáló hypothyreosisos tünetek esetén fontolják meg. Az újabb gyógyszerformákat a többség preferálja, ha az LT4 hagyományos tablettás formájának alacsonyabb biohasznosulása várható. Orv Hetil. 2022; 163(12): 463-472. INTRODUCTION: Hypothyroidism has a high prevalence in the adult population. Levothyroxine (LT4) supplementation is considered to be the gold-standard treatment method. In Hungary, LT4 tablets and soft gel capsules are the available formulations. Similarly to the international trends, hypothyroidism is earlier recognised, leading to early LT4 supplementation. Up till now, there has been no survey on the treatment of hypothyroidism among Hungarian endocrinologists. OBJECTIVE: THESIS (Treatment of Hypothyroidism in Europe by Specialists: an International Survey) had been conducted to assess treatment preferences among European endocrinologists. Here we report the results on the use of thyroid hormones in hypothyroid patients and euthyroid individuals in Hungary. METHOD: An e-mail invitation to participate, containing the link to the online survey was sent to members of the Hungarian Society for Endocrinology and Metabolism. RESULTS: There were 165 responses with full demographics which were included in the analysis. By the majority (99.4%) of them, LT4 was the first treatment of choice. LT4 + LT3 combination was considered an option in patients with persistent symptoms despite biochemical euthyroidism while on LT4 (36,1%). In euthyroid individuals, 60.3% of the respondents would consider starting LT4 in euthyroid infertile women with high antibody levels, which is hardly supported by evidence. In the presence of comorbidities and interfering medications which may hinder LT4 absorption, 66.4% of Hungarian endocrinologist anticipate significant improvement after switching from tablets to soft gel capsules. CONCLUSION: The treatment of choice for hypothyroidism is LT4 in Hungary. Combination therapy with LT4 + LT3 was considered for patients with persistent symptoms. In the presence of diseases and interfering medications affecting bioavailability, a high number of Hungarian endocrinologists prefer the new LT4 formulation. The administration of LT4 in euthyroid conditions awaits explanation and calls for intensive discussions at local conferences and courses. Orv Hetil. 2022; 163(12): 463-472.


Assuntos
Hipotireoidismo , Infertilidade Feminina , Médicos , Adulto , Feminino , Humanos , Hungria , Hipotireoidismo/tratamento farmacológico , Inquéritos e Questionários , Tiroxina/uso terapêutico
5.
Orv Hetil ; 161(2): 75-79, 2020 Jan.
Artigo em Húngaro | MEDLINE | ID: mdl-31902232

RESUMO

The authors present the case of a multiplex endocrine neoplasia type 2A (MEN2A). The 55-year-old woman underwent detailed examinations for abdominal complaints. Bilateral adrenal masses and thyroid nodular goiter were found. Based on metanephrine excretion and MIBG imaging, bilateral phaeochromocytomas were diagnosed. The thyroid nodules were confirmed by thyroidectomy as bilateral medullary thyroid carcinoma. Asymptomatic primary hyperparathyroidism was also detected. Laparoscopic adrenalectomy and parathyroid adenoma removal were performed. Based on family history and the characteristic clinical presentation, MEN2A syndrome was confirmed by genetic testing. During genetic screening of first-degree relatives, the patient's 25-year-old daughter was shown to be a gene carrier. Preventive thyroidectomy was performed and histology proved multifocal medullary thyroid cancer. In addition to the importance of genetic testing, the authors emphasize the guideline-based, but individualized approach to patients with suspected MEN2A syndrome. Orv Hetil. 2020; 161(2): 75-79.


Assuntos
Neoplasias das Glândulas Suprarrenais/cirurgia , Adrenalectomia , Neoplasia Endócrina Múltipla Tipo 2a/diagnóstico , Feocromocitoma , Neoplasias da Glândula Tireoide/diagnóstico por imagem , Nódulo da Glândula Tireoide/cirurgia , 3-Iodobenzilguanidina , Neoplasias das Glândulas Suprarrenais/patologia , Adulto , Feminino , Bócio Nodular , Humanos , Metanefrina , Pessoa de Meia-Idade , Neoplasia Endócrina Múltipla Tipo 2a/genética , Neoplasias das Paratireoides , Proteínas Ribossômicas , Neoplasias da Glândula Tireoide/genética , Nódulo da Glândula Tireoide/patologia , Tireoidectomia
7.
Orv Hetil ; 145(17): 891-9, 2004 Apr 25.
Artigo em Húngaro | MEDLINE | ID: mdl-15170966

RESUMO

Imaging of the extraocular muscles and orbital soft tissues in Graves' orbitopathy provides valuable information for both diagnosis and treatment decisions. However, assessment of the activity of the autoimmune process is often difficult. Currently available scoring systems for activity estimation are based merely on complaints and physical and ophthalmological examination. A reliable laboratory parameter correlating with disease activity is also missing. Sonography and magnetic resonance studies have pointed out, that thickening and/or edema of the extraocular muscles are often present before the onset of clinical symptoms and complaints. MRI and scintigraphy may provide important information upon the activity of the orbital process. Since the disease progrediates in the absence of therapy, it is essential to launch a properly timed immunosuppressive treatment in a selected group of patients. Based on their long-term experience in the Medical and Health Science Center of the University of Debrecen, Hungary, the authors review the currently available imaging methods in the diagnosis and follow up of endocrine orbitopathy, emphasizing their advantages and drawbacks.


Assuntos
Doença de Graves/diagnóstico , Doença de Graves/diagnóstico por imagem , Doença de Graves/fisiopatologia , Humanos , Imageamento por Ressonância Magnética , Testes de Função Tireóidea , Tomografia Computadorizada por Raios X , Ultrassonografia/métodos
8.
Orv Hetil ; 160(16): 636-637, 2019 04.
Artigo em Húngaro | MEDLINE | ID: mdl-30983398
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA